Advertisement
PFE vs SNY
Which Stock Would AI Choose? Pfizer Inc. (PFE) vs. Sanofi (SNY) Stock Comparison
Key Takeaways
- PFE has outperformed SNY year-to-date with approximately 12% gains compared to SNY's modest 1.5% rise, driven by oncology pipeline advancements.
- Both stocks trade at similar forward P/E ratios (price-to-earnings) around 20, indicating comparable valuations in the pharmaceutical sector.
- PFE's market capitalization exceeds $156 billion, larger than SNY's $115 billion, reflecting broader global exposure.
- Recent weeks show SNY gaining about 6% over the past month versus PFE's 2%, buoyed by immunology approvals.
- PFE benefits from momentum in weight loss and cancer treatments, while SNY focuses on Dupixent expansions.
- Tickeron's AI analysis leans toward PFE for superior trend consistency and growth catalysts in recent market activity.
Introduction
Pharmaceutical giants PFE (Pfizer Inc.) and SNY (Sanofi) represent cornerstone holdings in healthcare portfolios, offering exposure to innovative drugs, vaccines, and chronic disease treatments. This comparison evaluates their recent stock performance, business drivers, and market positioning amid shifting sector dynamics like oncology breakthroughs and immunology expansions. Traders seeking momentum plays and long-term investors eyeing dividend stability will find value in understanding their relative strengths, especially as both navigate post-pandemic revenue transitions and pipeline developments in recent market activity.
PFE Overview and Recent Performance
Pfizer Inc. (PFE), a leading biopharmaceutical company, specializes in vaccines, oncology, and internal medicine, with blockbuster products like Prevnar and ongoing COVID-19 therapeutics. In recent weeks, PFE shares have hovered around $27.50, up over 10% year-to-date and 33% over the past year, outperforming broader indices. This momentum stems from positive analyst initiations, such as CICC's Outperform rating, and pipeline progress including a Priority Review for PADCEV plus Keytruda in bladder cancer and potential Lyme disease vaccine advancements. Sentiment has improved despite COVID sales declines, fueled by explorations into obesity treatments challenging established GLP-1 leaders, enhancing long-term growth prospects.
SNY Overview and Recent Performance
Sanofi (SNY), a diversified global healthcare firm, excels in immunology, rare diseases, and consumer health, anchored by Dupixent collaborations with Regeneron. Shares trade near $48, with about 1.5% year-to-date gains and roughly 6% monthly appreciation in recent market activity, reflecting stability amid volatility. Key influences include EU approvals for Dupixent in pediatric urticaria and expansions into radiopharmaceuticals via partnerships like Telix. Upcoming Q1 2026 earnings on April 23 add anticipation, while collaborations in oncology, AI-driven discovery, and protein degradation bolster pipeline diversity. Investor sentiment remains steady, supported by consistent dividend payouts despite modest YTD returns.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI-powered trading bots from a library of over 350, meticulously curated for current market conditions based on real-time performance. These bots employ diverse strategies like swing trading, trend following, and leveraged ETF plays, with annualized returns ranging from 15% to 168%, win rates of 54% to 88%, and profit factors up to 11.7. They target sectors from semiconductors to aerospace, using technical and fundamental analysis across short (1-day) to medium (55-day) timeframes. Traders can copy these high-performing agents for automated execution, potentially capturing market swings efficiently. Explore the Trending AI Robots to identify bots aligning with your risk profile and timeframe.
Head-to-Head Comparison
Both PFE and SNY operate in the large-cap pharmaceutical space, but diverge in focus: PFE emphasizes vaccines and oncology amid pipeline diversification, while SNY prioritizes immunology via Dupixent and rare disease therapies. Growth drivers contrast with PFE's obesity and cancer catalysts versus SNY's partnership-driven approvals. Recent momentum favors PFE on YTD basis, though SNY shows short-term strength. Risk factors include patent cliffs for both, but PFE faces steeper COVID revenue drops. Sector exposure is similar in healthcare, yet PFE garners stronger market sentiment from U.S.-centric innovations.
Tickeron AI Verdict
Tickeron’s AI models currently favor PFE over SNY, citing superior year-to-date trend consistency, oncology momentum, and relative valuation stability. While SNY offers defensive positioning through diversified partnerships, PFE's catalysts like potential weight loss entries provide higher probabilistic upside in prevailing conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PFE is a Hold and SNY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PFE’s FA Score shows that 1 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).
- PFE’s FA Score: 1 green, 4 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PFE’s TA Score shows that 2 TA indicator(s) are bullish while SNY’s TA Score has 2 bullish TA indicator(s).
- PFE’s TA Score: 2 bullish, 6 bearish.
- SNY’s TA Score: 2 bullish, 8 bearish.
Price Growth
PFE (@Pharmaceuticals: Major) experienced а -3.67% price change this week, while SNY (@Pharmaceuticals: Major) price change was -3.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
PFE is expected to report earnings on Aug 04, 2026.
SNY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| PFE | SNY | PFE / SNY | |
| Capitalization | 144B | 101B | 143% |
| EBITDA | 17.2B | 8.52B | 202% |
| Gain YTD | 4.640 | -7.701 | -60% |
| P/E Ratio | 19.24 | 18.43 | 104% |
| Revenue | 63.3B | 47.4B | 134% |
| Total Cash | 13.1B | 5.54B | 236% |
| Total Debt | 63.7B | 20B | 319% |
PFE | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 78 | 71 | |
PRICE GROWTH RATING 1..100 | 56 | 60 | |
P/E GROWTH RATING 1..100 | 41 | 41 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as PFE (5). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.
SNY's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PFE (100). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.
SNY's SMR Rating (71) in the Pharmaceuticals Major industry is in the same range as PFE (78). This means that SNY’s stock grew similarly to PFE’s over the last 12 months.
PFE's Price Growth Rating (56) in the Pharmaceuticals Major industry is in the same range as SNY (60). This means that PFE’s stock grew similarly to SNY’s over the last 12 months.
PFE's P/E Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as SNY (41). This means that PFE’s stock grew similarly to SNY’s over the last 12 months.
| PFE | SNY | |
|---|---|---|
| RSI ODDS (%) | N/A | 20 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 57% | 3 days ago 54% |
| Momentum ODDS (%) | 3 days ago 52% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 47% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 50% |
| TrendMonth ODDS (%) | 3 days ago 54% | 3 days ago 43% |
| Advances ODDS (%) | 9 days ago 56% | 9 days ago 50% |
| Declines ODDS (%) | 3 days ago 58% | 3 days ago 49% |
| BollingerBands ODDS (%) | 5 days ago 59% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 58% | 3 days ago 55% |
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -2.74% | ||
| BMY - PFE | 59% Loosely correlated | -2.32% | ||
| MRK - PFE | 55% Loosely correlated | -1.36% | ||
| AMGN - PFE | 53% Loosely correlated | -1.19% | ||
| NVS - PFE | 53% Loosely correlated | -2.52% | ||
| BIIB - PFE | 51% Loosely correlated | -1.05% | ||
More | ||||
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with NVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then NVS could also see price increases.